

LARGE: RED (L); SMALL-MEDIUM: BLUE (SM); CSA: ORANGE (CSA); SME-targeted project PURPLE (SME); NETWORK OF EXCELLENCE: GREEN (NoE); SICA-BLACK; ERA-NETs: GREY (ERA-NET)

1ST CALL-2007 - FP7-HEALTH-2007-A CLOSED LINK: <a href="http://bit.ly/mSITrp">http://bit.ly/mSITrp</a>	2ND CALL-2008 - FP7-HEALTH-2007-B CLOSED LINK: <a href="http://bit.ly/mSITrp">http://bit.ly/mSITrp</a>	3RD CALL-2009 - FP7-HEALTH-2009 CLOSED LINK: <a href="http://bit.ly/jJkR2q">http://bit.ly/jJkR2q</a>	4TH CALL - 2010 CLOSED LINK: <a href="http://bit.ly/meb1qo">http://bit.ly/meb1qo</a>	5TH CALL - 2011 CLOSED LINK: <a href="http://bit.ly/8PHrY">http://bit.ly/8PHrY</a>	6TH CALL - 2012 DRAFT LINK: <a href="http://bit.ly/kFmvAx">http://bit.ly/kFmvAx</a>	7TH CALL - 2013
ACTIVITY 1. BIOTECHNOLOGY, GENERIC TOOLS AND MEDICAL TECHNOLOGIES FOR HUMAN HEALTH	ACTIVITY 1. BIOTECHNOLOGY, GENERIC TOOLS AND MEDICAL TECHNOLOGIES FOR HUMAN HEALTH	ACTIVITY 1. BIOTECHNOLOGY, GENERIC TOOLS AND MEDICAL TECHNOLOGIES FOR HUMAN HEALTH	ACTIVITY 1. BIOTECHNOLOGY, GENERIC TOOLS AND MEDICAL TECHNOLOGIES FOR HUMAN HEALTH	ACTIVITY 1. BIOTECHNOLOGY, GENERIC TOOLS AND MEDICAL TECHNOLOGIES FOR HUMAN HEALTH	ACTIVITY 1. BIOTECHNOLOGY, GENERIC TOOLS AND MEDICAL TECHNOLOGIES FOR HUMAN HEALTH	ACTIVITY 1. BIOTECHNOLOGY, GENERIC TOOLS AND MEDICAL TECHNOLOGIES FOR HUMAN HEALTH
AREA 1.1. HIGH-THROUGHPUT RESEARCH	AREA 1.1. HIGH-THROUGHPUT RESEARCH	AREA 1.1. HIGH-THROUGHPUT RESEARCH	AREA 1.1. HIGH-THROUGHPUT RESEARCH	AREA 1.1. HIGH-THROUGHPUT RESEARCH	AREA 1.1. HIGH-THROUGHPUT RESEARCH	AREA 1.1. HIGH-THROUGHPUT RESEARCH
HEALTH-2007-1.1-1: Unifying human and model organism genetic variation databases. (L)	HEALTH-2007-1.1-4: SME-driven collaborative research projects for developing tools and technologies for high-throughput research. (SM-SME)	HEALTH-2009-1.1-1: Computational tools for genome annotation and genotype/phenotype data integration. (L)	HEALTH-2010-1.1-1. Harmonisation of phenotyping and biosampling for human large-scale research biobanks (L)	HEALTH.2011.1.1-1: SME-targeted research for developing tools and technologies for high-throughput research (SM-SME-6+)	Closed	Open
HEALTH-2007-1.1-2: Temporal and spatial proteomics to study biological processes relevant to human health. (L)		HEALTH-2009-1.1-2: High throughput tools and technologies to analyse samples in large-scale human biobanks. (L)	HEALTH-2010-1.1-2. Genomics and Genetic Epidemiology of Multifactorial Disease (ERANET)	HEALTH-2011-1.1-2: Genome-based biomarkers for patient stratification and pharmacogenomic strategies (SM-SME-6+)	Closed	
HEALTH-2007-1.1-3: Groundbreaking techniques for DNA sequencing and genotyping. (L)		HEALTH-2009-1.1-3: Tools, technologies and resources for the characterisation of protein functions (L)	HEALTH-2010-1.1-3. High-throughput analysis of post-translational modifications of proteins (SM-3-CHINA)	HEALTH.2011.1.1-3: High-throughput proteomics for human health and disease (SM-3+)	Closed	
AREA 1.2. DETECTION, DIAGNOSIS AND MONITORING	AREA 1.2. DETECTION, DIAGNOSIS AND MONITORING	AREA 1.2. DETECTION, DIAGNOSIS AND MONITORING	AREA 1.2. DETECTION, DIAGNOSIS AND MONITORING	AREA 1.2. DETECTION, DIAGNOSIS AND MONITORING	AREA 1.2. DETECTION, DIAGNOSIS AND MONITORING	AREA 1.2. DETECTION, DIAGNOSIS AND MONITORING
HEALTH-2007-1.2-1: Development of a hybrid imaging system. (SM)	HEALTH-2007-1.2-5: Standardisation and improvement of pre-analytical procedures for in vitro diagnostics. (L)	HEALTH-2009-1.2-1: Development of tools for sensitive and specific in vitro detection of proteins and their interactions for diagnostic, prognostics and monitoring purposes. (SM)	HEALTH-2010-1.2-1. Tools for the identification and the detection of biomarkers in clinical samples and patients (SM-6)		HEALTH.2012.1.2-1: Development of technologies with a view to patient group stratification for personalised medicine applications. FP7-HEALTH-2012-INNOVATION-1. (30%SME-6+)	Closed
HEALTH-2007-1.2-2: Novel optical methodologies for detection, diagnosis and monitoring of disease or disease-related processes. (SM)	HEALTH-2007-1.2-6: High throughput molecular diagnostics in individual patients for genetic diseases with heterogeneous clinical presentation. (SM)	HEALTH-2009-1.2-2: Design of methods suited to identify epigenetic factors and their use in the genetic diagnosis of relevant disorders. (SM)	HEALTH-2010-1.2-2. Stratification approaches and methodologies to select from a wide range of biomarkers relevant candidates for clinical validation (SA)			
HEALTH-2007-1.2-3: Novel targeted imaging probes for early in vivo diagnosis and/or evaluation of response to therapy. (L)		HEALTH-2009-1.2-3: Novel MR-compatible PET detectors for simultaneous PET/MRI imaging. (L)	HEALTH-2010-1.2-3. Harmonization, validation and standardisation in genetic testing (CA)			
HEALTH-2007-1.2-4: In vivo image-guidance for cell therapy. (L)		HEALTH-2009-1.2-4: Novel imaging systems for in vivo monitoring and quality control during tumour ion beam therapy. (SM)	HEALTH-2010-1.2-4. Early events in acute hepatitis C virus (HCV) infection with the aim to identify new biomarkers (SM-3-MPC)			
		HEALTH-2009-1.2-5: Activatable or smart in vivo imaging agents reporting on physico-chemical or molecular changes relevant to the diagnosis and/or monitoring of diseases. (SM)				
		HEALTH-2009-1.2-6: Evaluation of the potential health impact of diagnostic imaging agents doses. (CSA)				
AREA 1.3 SUITABILITY, SAFETY, EFFICACY OF THERAPIES	AREA 1.3 SUITABILITY, SAFETY, EFFICACY OF THERAPIES	AREA 1.3 SUITABILITY, SAFETY, EFFICACY OF THERAPIES	AREA 1.3 SUITABILITY, SAFETY, EFFICACY OF THERAPIES	AREA 1.3 SUITABILITY, SAFETY, EFFICACY OF THERAPIES	AREA 1.3 SUITABILITY, SAFETY, EFFICACY OF THERAPIES	AREA 1.3 SUITABILITY, SAFETY, EFFICACY OF THERAPIES
HEALTH-2007-1.3-1: Novel alternative testing strategies for use in pharmaceutical discovery and development. (L)		HEALTH-2009-1.3-1: New initiatives towards the implementation of the Replace, Reduce and Refine strategy. (CSA)			Closed	Open
HEALTH-2007-1.3-2: Bottlenecks in reduction, refinement and replacement of animal testing in pharmaceutical discovery and development. (CSA)					Closed	
HEALTH-2007-1.3-3: Promotion, development, validation, acceptance and implementation of QSARs (quantitative structure-activity relationship) for toxicology. (SM)					Closed	
HEALTH-2007-1.3-4: Alternative testing strategies for the assessment of the toxicological profile of nanoparticles used in medical diagnostics. (SM)					Closed	
HEALTH-2007-1.3-5: In silico modelling for ADMET outcomes - NOT COVERED. (L)					Closed	
AREA 1.4 INNOVATIVE THERAPEUTIC APPROACHES AND INTERVENTIONS	AREA 1.4 INNOVATIVE THERAPEUTIC APPROACHES AND INTERVENTIONS	AREA 1.4 INNOVATIVE THERAPEUTIC APPROACHES AND INTERVENTIONS	AREA 1.4 INNOVATIVE THERAPEUTIC APPROACHES AND INTERVENTIONS	AREA 1.4 INNOVATIVE THERAPEUTIC APPROACHES AND INTERVENTIONS	AREA 1.4 INNOVATIVE THERAPEUTIC APPROACHES AND INTERVENTIONS	AREA 1.4 INNOVATIVE THERAPEUTIC APPROACHES AND INTERVENTIONS
HEALTH-2007-1.4-1: Development and production of new generation antibodies. (SM)	HEALTH-2007-1.4-4: Development of emerging gene therapy tools and technologies for clinical application. (L)	HEALTH-2009-1.4-1: Cell therapy for tissue and organs. (L)	HEALTH-2010-1.4-1. Translational research on cell-based immunotherapy (L)	HEALTH.2011.1.4-1: Regenerative medicine clinical trials (SM-6+)	HEALTH.2012.1.4-1: Innovative approaches to solid organ transplantation. FP7-HEALTH-2012-INNOVATION-1. (SM-15%SME-6+)	

HEALTH-2007-1.4-2: Innovative approaches for the development of vaccines for young children. (SM)	HEALTH-2007-1.4-5: Gene therapy tools targeting the central nervous system. (SM)	HEALTH-2009-1.4-2: Regeneration of tissue using bio-compatible materials and cells. (L)		HEALTH.2011.1.4-2: Tools, technologies and devices for regenerative medicine (SM-6+)	HEALTH.2012.1.4-2: Medical technology for transplantation and bioartificial organs. FP7-HEALTH-2012-INNOVATION-2. (SM-50%SME-6+)	Closed
HEALTH-2007-1.4-3: Immunotherapy of human food allergies. (SM)	HEALTH-2007-1.4-6: Stem cell lines for cell-based therapies. (L)	HEALTH-2009-1.4-3: Activation of endogenous cells as an approach to regenerative medicine. (L)		HEALTH.2011.1.4-3: Development and production of new, high-affinity protein scaffolds as an alternative to antibodies (SM-6+)	HEALTH.2012.1.4-3: Innovative Strategies for translation of stem cell based therapies in regenerative medicine (European Union-Australia cooperation). FP7-HEALTH-2012-INNOVATION-1. (SM-15%SME-6+)	
	HEALTH-2007-1.4-7: Development of stem cell culture conditions. (SM)			HEALTH.2011.1.4-4: High priority initiative for better and safer immunisation (L-30)	HEALTH.2012.1.4-4: Targeted nucleic acid delivery as an innovative therapeutic or prophylactic approach. FP7-HEALTH-2012-INNOVATION-1. (SM-30%Industries-6+)	
	HEALTH-2007-1.4-8: Stem cells for kidney regeneration. (SM)			HEALTH.2011.1.4-5: New therapeutic approaches in chronic inflammatory and autoimmune diseases (SM-3+)		
	HEALTH-2007-1.4-9: Adding value to EU stem cell therapy research: scientific communication and future perspectives. NOT COVERED. (CSA)					
ACTIVITY 2. TRANSLATING RESEARCH FOR HUMAN HEALTH	ACTIVITY 2. TRANSLATING RESEARCH FOR HUMAN HEALTH	ACTIVITY 2. TRANSLATING RESEARCH FOR HUMAN HEALTH	ACTIVITY 2. TRANSLATING RESEARCH FOR HUMAN HEALTH	ACTIVITY 2. TRANSLATING RESEARCH FOR HUMAN HEALTH	ACTIVITY 2. TRANSLATING RESEARCH FOR HUMAN HEALTH	ACTIVITY 2. TRANSLATING RESEARCH FOR HUMAN HEALTH
AREA 2.1. INTEGRATING BIOLOGICAL DATA AND PROCESSES: LARGE-SCALE DATA GATHERING, SYSTEMS BIOLOGY	AREA 2.1. INTEGRATING BIOLOGICAL DATA AND PROCESSES: LARGE-SCALE DATA GATHERING, SYSTEMS BIOLOGY	AREA 2.1. INTEGRATING BIOLOGICAL DATA AND PROCESSES: LARGE-SCALE DATA GATHERING, SYSTEMS BIOLOGY	AREA 2.1. INTEGRATING BIOLOGICAL DATA AND PROCESSES: LARGE-SCALE DATA GATHERING, SYSTEMS BIOLOGY	AREA 2.1. INTEGRATING BIOLOGICAL DATA AND PROCESSES: LARGE-SCALE DATA GATHERING, SYSTEMS BIOLOGY	AREA 2.1. INTEGRATING BIOLOGICAL DATA AND PROCESSES: LARGE-SCALE DATA GATHERING, SYSTEMS BIOLOGY	AREA 2.1. INTEGRATING BIOLOGICAL DATA AND PROCESSES: LARGE-SCALE DATA GATHERING, SYSTEMS BIOLOGY
2.1.1. LARGE-SCALE DATA GATHERING	2.1.1. LARGE-SCALE DATA GATHERING	2.1.1. LARGE-SCALE DATA GATHERING	2.1.1. LARGE-SCALE DATA GATHERING	2.1.1. LARGE-SCALE DATA GATHERING	2.1.1. LARGE-SCALE DATA GATHERING	2.1.1. LARGE-SCALE DATA GATHERING
HEALTH-2007-2.1.1-1: Networking biobanking initiatives across Europe: developing standards and norms for existing and future human sample biobanks. NOT COVERED (L)		HEALTH-2009-2.1.1-1: Large-scale functional genomics effort in multi-cellular organisms to elucidate the function of human genes products. (L)	HEALTH-2010-2.1.1-1. Large-scale efforts in mouse functional genomics to determine the functions of genes and their involvement in disease (L)	HEALTH.2011.2.1.1-1: High impact initiative on the human epigenome (L-30)	HEALTH.2012.2.1.1-1-A: Support for international rare disease research. FP7-HEALTH-2012-INNOVATION-1. (CSA+2)	Open
HEALTH-2007-2.1.1-2: Molecular epidemiological studies in existing well characterised European (and/or other) population cohorts. (L)		HEALTH-2009-2.1.1-2: Large-scale functional genomics efforts to identify molecular determinants of cancer (L)	HEALTH-2010-2.1.1-2. Coordination action(s) on standards in large scale data gathering (CA)	HEALTH.2011.2.1.1-2: Proteins and their interactions in health and disease (L-12+)	HEALTH.2012.2.1.1-1-B: Clinical utility of -omics for better diagnosis of rare diseases. FP7-HEALTH-2012-INNOVATION-1 (L-30%SME-12+)	
HEALTH-2007-2.1.1-3: Comparative studies of genetic variation in humans: towards a reference population in Europe. NOT COVERED. (L)		HEALTH-2009-2.1.1-3: Characterisation of human genetic variation in Europe (L)		HEALTH.2011.2.1.1-3: Large-scale genomics approaches to identify host determinants of infectious diseases (L-12)	HEALTH.2012.2.1.1-1-C: Databases, biobanks and 'clinical bio-informatics' hub for rare diseases. FP7-HEALTH-2012-INNOVATION-1. (L-12)	
HEALTH-2007-2.1.1-4: Characterisation and variability of the microbial communities in the Human Body. (L)				HEALTH.2011.2.1.1-4: Population genetic studies on cardio-metabolic disorders in EU/AC and EECA populations (SM-SICA-6)	HEALTH.2012.2.1.1-2: Validation of -omics-based biomarkers for diseases affecting the elderly. FP7-HEALTH-2012-INNOVATION-1. (30%SME-12+)	
HEALTH-2007-2.1.1-5: Structure-function analysis of membrane-transporters and channels for the identification of potential drug target sites. (L)					HEALTH.2012.2.1.1-3: Statistical methods for collection and analysis of -omics data. FP7-HEALTH-2012-INNOVATION-1. (15%SME-6+)	
HEALTH-2007-2.1.1-6: High throughput analysis of lipids and lipid-protein interactions. (L)						
HEALTH-2007-2.1.1-7: Genome-wide association studies in mammalian non-rodent models for the identification of genes relevant to human health and disease. (L)						
2.1.2. SYSTEMS BIOLOGY	2.1.2. SYSTEMS BIOLOGY	2.1.2. SYSTEMS BIOLOGY	2.1.2. SYSTEMS BIOLOGY	2.1.2. SYSTEMS BIOLOGY	2.1.2. SYSTEMS BIOLOGY	2.1.2. SYSTEMS BIOLOGY
HEALTH-2007-2.1.2-1: A system approach to eukaryotic unicellular organism biology. (L)	HEALTH-2007-2.1.2-5: Multidisciplinary fundamental genomics and molecular biology approaches to study basic biological processes relevant to health and diseases. (SM)	HEALTH-2009-2.1.2-1: Systems biology approaches for basic biological processes relevant to health and disease. (L)	HEALTH-2010-2.1.2-1. Tackling Human Diseases through Systems Biology Approaches (L)		HEALTH.2012.2.1.2-1: Systems medicine: SME-driven research applying systems biology approaches to address medical and clinical needs. FP7-HEALTH-2012-INNOVATION-1. (30%SME-3+)	Closed
HEALTH-2007-2.1.2-2: Modelling of T-cell activation. (L)	HEALTH-2007-2-1-2-6: Coordination and Support Actions in large-scale data gathering and systems biology. (CSA)		HEALTH-2010-2.1.2-2. Establishing the foundations to enable systems biology of complex biological processes relevant to human health (NoE)		HEALTH.2012.2.1.2-2: Systems medicine: Applying systems biology approaches for understanding multifactorial human diseases and their co-morbidities. FP7-HEALTH-2012-INNOVATION-1. (L-30%SME-12+)	
HEALTH-2007-2.1.2-3: Fundamental approaches to stem cell differentiation. (L)	HEALTH-2007-2.1.2-7: Traditional Chinese Medicine in post-genomic era. (CSA)		HEALTH-2010-2.1.2-3. Developing new and improving existing mathematical algorithms for systems biology (SM-3-EECA)		HEALTH.2012.2.1.2-3: Preparing for the future research and innovation activities in systems medicine. FP7-HEALTH-2012-INNOVATION-1. (CSA,3)	
HEALTH-2007-2.1.2-4: Developing an integrated in vitro, in vivo and systems biology modelling approach to understanding apoptosis in the context of health and disease. (L)						



HEALTH-2007-2.3.2-1: HIV/AIDS Drug Discovery and Preclinical Development. (SM)	HEALTH-2007-2.3.2-7: Network on HIV and anti-HIV drug resistance. (L)	HEALTH-2009-2.3.2-1: Integration of European efforts in research on malaria. (NoE)	HEALTH-2010-2.3.2-1. Target characterization and hit-to-lead progression in tuberculosis (TB) drug development (L)		HEALTH.2012.2.3.2-1: Co-infection of HIV/AIDS, malaria, tuberculosis and/or hepatitis. FP7-HEALTH-2012-INNOVATION-1 (SM-6+)	Closed
HEALTH-2007-2.3.2-2: Highly innovative approaches for research into host-pathogen interaction in tuberculosis. (SM)	HEALTH-2007-2.3.2-8: HIV and Hepatitis co-infection. NOT COVERED - (CSA)	HEALTH-2009-2.3.2-2: Identification and pre-clinical testing of new vaccine candidates for tuberculosis. (L)	HEALTH-2010-2.3.2-2. Lead optimization and late preclinical development in tuberculosis (TB) drugs (SM-6)		HEALTH.2012.2.3.2-2: Co-morbidity between infectious and non-communicable diseases. FP7-HEALTH-2012-INNOVATION-1 (SM-6+)	
HEALTH-2007-2.3.2-3: Development of fast tests for the diagnosis of Multi-Drug-Resistant strains of HIV, malaria and tuberculosis and of latent tuberculosis infection (LTBI). (SM)	HEALTH-2007-2.3.2-9: Blocking the transmission of malaria: the mosquito vector target. (SM)	HEALTH-2009-2.3.2-3: Discovery and/or development of new and promising anti-HIV microbicides. (L)	HEALTH-2010-2.3.2-3. European network of cohorts studies on HIV/AIDS (NoE)		HEALTH.2012.2.3.2-3: Prevention and treatment for HIV/AIDS, malaria and tuberculosis. FP7-HEALTH-2012-INNOVATION-1 (15%SME-6+)	
HEALTH-2007-2.3.2-4: Addressing knowledge gaps in pregnancy malaria. (SM)	HEALTH-2007-2.3.2-10: European network for study and clinical management of TB drug resistance. (L)	HEALTH-2009-2.3.2-4: Mucosal and topical vaccines for poverty-related diseases (HIV/AIDS, malaria and/or TB). (L)	HEALTH-2010-2.3.2-4. Controlling Malaria by Hitting the Vector: New or Improved – Vector Control Tools (L-ICPC)		HEALTH.2012.2.3.2-4: Low-cost interventions for disease control in resource poor settings. FP7-HEALTH-2012-INNOVATION-1 (SM-3+)	
HEALTH-2007-2.3.2-5: Paediatric formulations of drugs against HIV/AIDS, malaria and tuberculosis. (CSA)	HEALTH-2007-2.3.2-11: Support platform for the development of PRD vaccines. (CSA)	HEALTH-2009-2.3.2-5: Translational vaccine research for poverty-related diseases (HIV/AIDS, malaria and/or TB). (SM)				
HEALTH-2007-2.3.2-6: New HIV Vaccines inducing broadly-reactive neutralising antibodies. (L)	HEALTH-2007-2.3.2-12: Highly innovative research in HIV/AIDS, malaria and tuberculosis between Indian and European partners (SICA), (SM)	HEALTH-2009-2.3.2-6: ERA-NET for stepping up European co-operation in HIV/AIDS research				
	HEALTH-2007-2.3.2-13: Coordination of European research activities with global initiatives, including Public-Private Partnerships (SICA) - (CSA)					
	HEALTH-2007-2.3.2-14: Next generation of researchers for HIV/AIDS, malaria, tuberculosis and neglected infectious diseases (SICA) - (CSA)					
2.3.3. POTENTIALLY NEW AND RE-EMERGING EPIDEMICS	2.3.3. POTENTIALLY NEW AND RE-EMERGING EPIDEMICS	2.3.3. POTENTIALLY NEW AND RE-EMERGING EPIDEMICS	2.3.3. POTENTIALLY NEW AND RE-EMERGING EPIDEMICS	2.3.3. POTENTIALLY NEW AND RE-EMERGING EPIDEMICS	2.3.3. POTENTIALLY NEW AND RE-EMERGING EPIDEMICS	2.3.3. POTENTIALLY NEW AND RE-EMERGING EPIDEMICS
HEALTH-2007-2.3.3-1: Development of broadly protective influenza vaccine candidates. (SM)	HEALTH-2007-2.3.3-9: Strengthening research on prediction, identification, modelling and surveillance of newly emerging infectious diseases in humans. (L)	HEALTH-2009-2.3.3-1: Efficacy and effectiveness of personal protection equipment and other measures against influenza transmission. (SM)	HEALTH-2010-2.3.3-1. Biology and control of vector-borne infections in Europe (L)	HEALTH.2011.2.3.3-1: Identification of factors promoting the emergence of viruses with human pandemic potential from viruses with a zoonotic background and related prevention strategies (L-12)	Closed	Open
HEALTH-2007-2.3.3-2: Identifying immunological mechanisms of protection for influenza vaccines. (SM)	HEALTH-2007-2.3.3-10: Definition of research needs and priorities in Europe in the area of Emerging Infectious Epidemics. NOT COVERED - (CSA)		HEALTH-2010-2.3.3-2. Drug lead discovery against RNA viruses (L)	HEALTH.2011.2.3.3-2 Comprehensive control of Dengue fever under changing climatic conditions (SM-SICA-6+)	Closed	
HEALTH-2007-2.3.3-3: Standardisation of immunological assays including surrogate markers for evaluation of new influenza vaccines in clinical trials. NOT COVERED - (CSA)			HEALTH-2010-2.3.3-3. Integrated disease-specific research on West Nile Virus infections, Chikungunya and/or Crimean Congo Haemorrhagic Fever (SM-3)	HEALTH.2011.2.3.3-3: Development of an evidence-based behavioural and communication package to respond to major epidemic outbreaks (SM-3)	Closed	
HEALTH-2007-2.3.3-4: Innovative point-of-care diagnostic tests for influenza. (SM-SME)			HEALTH-2010-2.3.3-4. Novel therapeutics against influenza (SM-6)		Closed	
HEALTH-2007-2.3.3-5: Development of additional treatment strategies for patients suffering from highly pathogenic influenza. NOT COVERED - (SM)					Closed	
HEALTH-2007-2.3.3-6: Development of pandemic influenza containment and mitigation strategies. (SM)					Closed	
HEALTH-2007-2.3.3-7: Supporting highly innovative inter-disciplinary research on influenza. (SM)					Closed	
HEALTH-2007-2.3.3-8: Influenza research in collaboration with Asian partners (SICA) (SM)					Closed	
2.3.4. NEGLECTED INFECTIOUS DISEASES	2.3.4. NEGLECTED INFECTIOUS DISEASES	2.3.4. NEGLECTED INFECTIOUS DISEASES	2.3.4. NEGLECTED INFECTIOUS DISEASES	2.3.4. NEGLECTED INFECTIOUS DISEASES	2.3.4. NEGLECTED INFECTIOUS DISEASES	2.3.4. NEGLECTED INFECTIOUS DISEASES
	HEALTH-2007-2.3.4-1: Development of new tools to control infections due to parasites of the Trypanosomatidae family. (SICA) - (SM)	HEALTH-2009-4.3.1-1: Discovery and development of new vaccines or drugs for helminth infections (SICA), (SM)	HEALTH-2010-2.3.4-1. Vaccines for childhood bacterial diarrhoeal diseases (L-ICPC)		Closed	Priority
	HEALTH-2007-2.3.4-2: Development of a Leishmania vaccine. (SICA) - (SM)	HEALTH-2009-4.3.1-2: Identification and development of vaccine candidates for neglected bacterial infections (SICA), (SM)	HEALTH-2010-2.3.4-2. Comprehensive control of Neglected Infectious Diseases (L-ICPC)		Closed	
	HEALTH-2007-2.3.4-3: Bioprospecting for drug leads. (SICA) - (SM)	HEALTH-2009-4.3.1-3: Human immune responses to co-infections of poverty-Related (HIV, malaria, TB) and neglected infectious diseases (SICA), (L)	HEALTH-2010-2.3.4-3. Next generation of researchers for Neglected Infectious Diseases (CA)		Closed	
AREA 2.4. TRANSLATIONAL RESEARCH IN OTHER MAJOR DISEASES	AREA 2.4. TRANSLATIONAL RESEARCH IN OTHER MAJOR DISEASES	AREA 2.4. TRANSLATIONAL RESEARCH IN OTHER MAJOR DISEASES	AREA 2.4. TRANSLATIONAL RESEARCH IN OTHER MAJOR DISEASES	AREA 2.4. TRANSLATIONAL RESEARCH IN OTHER MAJOR DISEASES	AREA 2.4. TRANSLATIONAL RESEARCH IN OTHER MAJOR DISEASES	AREA 2.4. TRANSLATIONAL RESEARCH IN OTHER MAJOR DISEASES
2.4.1. CANCER	2.4.1. CANCER	2.4.1. CANCER	2.4.1. CANCER	2.4.1. CANCER	2.4.1. CANCER	2.4.1. CANCER
HEALTH-2007-2.4.1-1: Translating the knowledge on non-coding RNAs linked to the aetiology of cancer into novel diagnosis and therapy strategies. (SM)	HEALTH-2007-2.4.1-9: Innovative combination clinical trials for multimodal cancer therapy. NOT COVERED - (L)		HEALTH-2010-2.4.1-1. ERA-NET on translational cancer research in Europe (ERANET)	HEALTH.2011. 2.4.1-1: Investigator-driven, treatment trials for rare cancers (SM-6+)	Closed	

HEALTH-2007-2.4.1-2: Translating clinical 'omics' technology (genomics, proteomics, metabolomics) into innovative cancer biomarkers aiding in early diagnosis, prognosis and treatment selection of cancer patients. (SM)	HEALTH-2007-2.4.1-10: Role of inflammation in tumour initiation and progression. (L)		HEALTH-2010-2.4.1-2. Structuring translational cancer research between cancer research centres in Europe (NoE)	HEALTH.2011.2.4.1-2: Translational research on cancers with poor prognosis (SM-3+)	Closed	Priority
HEALTH-2007-2.4.1-3: Genomic instability and genomic alterations in pre-cancerous lesions and/or cancer. (SM)	HEALTH-2007-2.4.1-11: Epidemiology of gene-environment interactions involved in carcinogenesis. (L)		HEALTH-2010-2.4.1-3. Structuring clinical research in paediatric and adolescent oncology in Europe (NoE)	HEALTH.2011.2.4.1-3: Aetiology and epidemiology of cancer caused by infectious agents in the Indian population (SM-SICA-3+)	Closed	
HEALTH-2007-2.4.1-4: Novel cancer screening methods. (SM)	HEALTH-2007-2.4.1-12: Translating the hypoxic tumour microenvironment. (L)		HEALTH-2010-2.4.1-4. Infectious agents and cancer in Africa (SM-3-ICPC)		Closed	
HEALTH-2007-2.4.1-5: Optimising research on end of life care of cancer patients. (CSA)	HEALTH-2007-2.4.1-14: Studying cancer aetiology in Latin America. (SICA) - (SM)		HEALTH-2010-2.4.1-5. Structuring clinical trials on rare cancers in adults (SM-6)		Closed	
HEALTH-2007-2.4.1-6: Understanding and fighting metastasis. (SM)	HEALTH-2007-2.4.1-13: ERA-NET on optimisation of the use of cancer registries for cancer research purposes		HEALTH-2010-2.4.1-6. Translational research on common cancers with poor-prognosis (SM-3)		Closed	
HEALTH-2007-2.4.1-7: Improving targeted drug delivery to cancer cells for cancer therapeutics other than gene therapy. (SM)			HEALTH-2010-2.4.1-7. Predicting long-term side effects to cancer therapy (SM-6)		Closed	
HEALTH-2007-2.4.1-8: Developing high-throughput bioassays and models for human cancers in lower species. (SM)			HEALTH-2010-2.4.1-8. Predicting individual response and resistance to therapy (SM-6)		Closed	
			HEALTH-2010-2.4.1-9. Optimising the delivery of (chemo)radiotherapy and/or surgery to cancer patients (SM-6)		Closed	
2.4.2. CARDIOVASCULAR DISEASES	2.4.2. CARDIOVASCULAR DISEASES	2.4.2. CARDIOVASCULAR DISEASES	2.4.2. CARDIOVASCULAR DISEASES	2.4.2. CARDIOVASCULAR DISEASES	2.4.2. CARDIOVASCULAR DISEASES	2.4.2. CARDIOVASCULAR DISEASES
HEALTH-2007-2.4.2-1: Molecular basis of the inflammatory response and associated vascular remodelling in arteriosclerosis. (L)	HEALTH-2007-2.4.2-4: Congenital pathologies affecting the heart. (SM)	HEALTH-2009-2.4.2-1: Improved or new therapeutic approaches for the treatment of heart failure. (L)	HEALTH-2010-2.4.2-1. Reducing in-stent thrombosis (SM-6)	HEALTH.2011. 2.4.2-1: Investigator-driven clinical trials for the management of cardiovascular diseases (L-12+)	Closed	Priority
HEALTH-2007-2.4.2-2: Vascular remodelling in aneurysmal disease. (L)	HEALTH-2007-2.4.2-5: Cell therapies for the treatment of heart ischemia. (SM)	HEALTH-2009-2.4.2-2: Cardiac arrhythmias: from genes to improved management of patients. (L)	HEALTH-2010-2.4.2-2. New approaches to reduce ischemic damage to the heart (SM-6)	HEALTH.2011.2.4.2-2: Novel prevention and treatment biomarkers for risk assessment in cardiovascular diseases (SM-6+)	Closed	
HEALTH-2007-2.4.2-3: Combating stroke. (L)	HEALTH-2007-2.4.2-6: Organ imaging in CVD. (SM)	HEALTH-2009-2.4.2-3: Translation of basic knowledge on inherited cardiomyopathies into clinical practice. (SM)	HEALTH-2010-2.4.2-3. Identifying new therapeutic targets in atrial fibrillation (L)		Closed	
	HEALTH-2007-2.4.2-7: Integrating pharmacogenomic approaches into the treatment of CVD. (SM)		HEALTH-2010-2.4.2-4. Diastolic heart failure (L)		Closed	
2.4.3. DIABETES AND OBESITY	2.4.3. DIABETES AND OBESITY	2.4.3. DIABETES AND OBESITY	2.4.3. DIABETES AND OBESITY	2.4.3. DIABETES AND OBESITY	2.4.3. DIABETES AND OBESITY	2.4.3. DIABETES AND OBESITY
HEALTH-2007-2.4.3-1: Early processes in the pathogenesis of type 1 diabetes and strategies for early prevention. (SM)	HEALTH-2007-2.4.3-6: Nutritional signals and the development of new diabetes/obesity therapeutic agents. (SM-SME)	HEALTH-2009-2.4.3-1: Novel therapeutical approach to pregnancy-induced diabetes. (SM)		HEALTH.2011.2.4.3-1: Investigator-driven clinical trials to reduce diabetes complications (SM-6+)	HEALTH.2012.2.4.3-1: Innovative approach to manage diabetes. FP7-HEALTH-2012-INNOVATION-1 (30%SME-6+)	Closed
HEALTH-2007-2.4.3-2: Combined forms of diabetes in children. NOT COVERED - (SM)	HEALTH-2007-2.4.3-7: Markers and treatment for diabetic neuropathy complications. (SM)	HEALTH-2009-2.4.3-2: Novel immunotherapies for type 1 diabetes. (L)		HEALTH.2011.2.4.3-2 Development of novel treatment strategies based on knowledge of beta cell dysfunction (SM-6+)	HEALTH.2012.2.4.3-2: Investigator-driven clinical trials for type 1 diabetes research. FP7-HEALTH-2012-INNOVATION-1. (SM-6+)	
HEALTH-2007-2.4.3-3: Insulin resistance as a key factor in the development of diabetes and metabolic syndrome. (SM)	HEALTH-2007-2.4.3-8: Geno- and phenotypical differentiation of type 2 subjects and monogenic subjects. (SM)	HEALTH-2009-2.4.3-3: Molecular pathways in food intake at CNS-liver-gut regulation level. (SM)		HEALTH.2011.2.4.3-3: Molecular and physiological effects of physical exercise on diabetes/obesity (SM-6)		
HEALTH-2007-2.4.3-4: Pathophysiological mechanisms related to excess fat. (SM)	HEALTH-2007-2.4.3-9: Use of beta cell imaging in diabetes mellitus. (SM)			HEALTH.2011.2.4.3-4: Genetic and environmental factors in obesity and/or diabetes in specific populations (SM-SICA-3+)		
HEALTH-2007-2.4.3-5: A road-map for diabetes research. (CSA)				HEALTH.2011.2.4.3-5: ERA-NET on diabetes prevention and treatment (2)		
2.4.4. RARE DISEASES	2.4.4. RARE DISEASES	2.4.4. RARE DISEASES	2.4.4. RARE DISEASES	2.4.4. RARE DISEASES	2.4.4. RARE DISEASES	2.4.4. RARE DISEASES
HEALTH-2007-2.4.4-1: Natural course and pathophysiology of rare diseases. (SM)		HEALTH-2009-2.4.4-1: Rare neurological diseases. (SM)	HEALTH-2010-2.4.4-1. Clinical development of substances with a clear potential as orphan drugs (SM-6)		HEALTH.2012.2.4.4-1: Preclinical and/or clinical development of substances with a clear potential as orphan drugs. FP7-HEALTH-2012-INNOVATION-1 (SM-30% industry-6+)	Closed
HEALTH-2007-2.4.4-2: Research capacity-building in the field of rare diseases. (CSA)		HEALTH-2009-2.4.4-2: Preclinical development of substances with a clear potential as orphan drugs. (SM)	HEALTH-2010-2.4.4-2. ERA-Net on rare diseases (ERANET)		HEALTH.2012.2.4.4-2: Observational trials[1] in rare diseases. FP7-HEALTH-2012-INNOVATION-1. (SM-3+)	
					HEALTH.2012.2.4.4-3: Best practice and knowledge sharing in the clinical management of rare diseases. FP7-HEALTH-2012-INNOVATION-1. (CSA-2+)	
2.4.5. OTHER CHRONIC DISEASES	2.4.5. OTHER CHRONIC DISEASES	2.4.5. OTHER CHRONIC DISEASES	2.4.5. OTHER CHRONIC DISEASES	2.4.5. OTHER CHRONIC DISEASES	2.4.5. OTHER CHRONIC DISEASES	2.4.5. OTHER CHRONIC DISEASES
HEALTH-2007-2.4.5-1: Osteoarthritis. (L)	HEALTH-2007-2.4.5-10: Understanding and combating age-related muscle weakness. (L)	HEALTH-2009-2.4.5-1: Prevention and treatment of non-alcoholic fatty liver disease (NAFLD). (SM)	HEALTH-2010-2.4.5-1. Investigation of the mechanisms of initiation of respiratory allergic response, genetic predisposition, biomarkers and identification of targets for therapy (L)		HEALTH.2012.2.4.5-1: Technological approaches to combating sensory impairments. FP7-HEALTH-2012-INNOVATION-2 (50%SME-6+)	Closed
HEALTH-2007-2.4.5-2: Inflammatory bowel disease. (SM)	HEALTH-2007-2.4.5-11: Translational research aiming for a treatment of urinary incontinence. (SM)	HEALTH-2009-2.4.5-2: Cellular and molecular mechanisms of the development of chronic kidney disease (CKD). (L)	HEALTH-2010-2.4.5-2. Infection and dysbiosis as the trigger for the development of inflammatory processes in allergies and autoimmune diseases (SM-6)		HEALTH.2012.2.4.5-2: Biomarkers and diagnostics for chronic inflammatory diseases of the joints and/or digestive system. FP7-HEALTH-2012-INNOVATION-1 (15%SME-6+)	

HEALTH-2007-2.4.5-3: Osteoporosis: signalling pathways in bone formation and homeostasis. (SM)	HEALTH-2007-2.4.5-12: Early processes in the pathogenesis of chronic inflammatory diseases. (L)					Closed
HEALTH-2007-2.4.5-4: Genetic factors of Osteoporosis. (SM)						
HEALTH-2007-2.4.5-5: Intervertebral disc degeneration: prevention and repair. (SM)						
HEALTH-2007-2.4.5-6: Innovative concepts in chronic obstructive pulmonary disease pathogenesis (COPD). (SM)						
HEALTH-2007-2.4.5-7: Hearing impairment and degeneration. NOT COVERED - (CSA)						
HEALTH-2007-2.4.5-8: Impairment of touch and proprioception at old age. (CSA)						
HEALTH-2007-2.4.5-9: Visual impairment and degeneration. (CSA)						
<b>ACTIVITY 3. OPTIMISING THE DELIVERY OF HEALTHCARE TO EUROPEAN CITIZENS</b>	<b>ACTIVITY 3. OPTIMISING THE DELIVERY OF HEALTHCARE TO EUROPEAN CITIZENS</b>	<b>ACTIVITY 3. OPTIMISING THE DELIVERY OF HEALTHCARE TO EUROPEAN CITIZENS</b>	<b>ACTIVITY 3. OPTIMISING THE DELIVERY OF HEALTHCARE TO EUROPEAN CITIZENS</b>	<b>ACTIVITY 3. OPTIMISING THE DELIVERY OF HEALTHCARE TO EUROPEAN CITIZENS</b>	<b>ACTIVITY 3. OPTIMISING THE DELIVERY OF HEALTHCARE TO EUROPEAN CITIZENS</b>	<b>ACTIVITY 3. OPTIMISING THE DELIVERY OF HEALTHCARE TO EUROPEAN CITIZENS</b>
<b>AREA 3.1. TRANSLATING THE RESULTS OF CLINICAL RESEARCH OUTCOME INTO CLINICAL PRACTICE INCLUDING BETTER USE OF MEDICINES, AND APPROPRIATE USE OF BEHAVIOURAL AND ORGANISATIONAL INTERVENTIONS AND NEW HEALTH THERAPIES AND TECHNOLOGIES</b>	<b>AREA 3.1. TRANSLATING THE RESULTS OF CLINICAL RESEARCH OUTCOME INTO CLINICAL PRACTICE INCLUDING BETTER USE OF MEDICINES, AND APPROPRIATE USE OF BEHAVIOURAL AND ORGANISATIONAL INTERVENTIONS AND NEW HEALTH THERAPIES AND TECHNOLOGIES</b>	<b>AREA 3.1. TRANSLATING THE RESULTS OF CLINICAL RESEARCH OUTCOME INTO CLINICAL PRACTICE INCLUDING BETTER USE OF MEDICINES, AND APPROPRIATE USE OF BEHAVIOURAL AND ORGANISATIONAL INTERVENTIONS AND NEW HEALTH THERAPIES AND TECHNOLOGIES</b>	<b>AREA 3.1. TRANSLATING THE RESULTS OF CLINICAL RESEARCH OUTCOME INTO CLINICAL PRACTICE INCLUDING BETTER USE OF MEDICINES, AND APPROPRIATE USE OF BEHAVIOURAL AND ORGANISATIONAL INTERVENTIONS AND NEW HEALTH THERAPIES AND TECHNOLOGIES</b>	<b>AREA 3.1. TRANSLATING THE RESULTS OF CLINICAL RESEARCH OUTCOME INTO CLINICAL PRACTICE INCLUDING BETTER USE OF MEDICINES, AND APPROPRIATE USE OF BEHAVIOURAL AND ORGANISATIONAL INTERVENTIONS AND NEW HEALTH THERAPIES AND TECHNOLOGIES</b>	<b>AREA 3.1. TRANSLATING THE RESULTS OF CLINICAL RESEARCH OUTCOME INTO CLINICAL PRACTICE INCLUDING BETTER USE OF MEDICINES, AND APPROPRIATE USE OF BEHAVIOURAL AND ORGANISATIONAL INTERVENTIONS AND NEW HEALTH THERAPIES AND TECHNOLOGIES</b>	<b>AREA 3.1. TRANSLATING THE RESULTS OF CLINICAL RESEARCH OUTCOME INTO CLINICAL PRACTICE INCLUDING BETTER USE OF MEDICINES, AND APPROPRIATE USE OF BEHAVIOURAL AND ORGANISATIONAL INTERVENTIONS AND NEW HEALTH THERAPIES AND TECHNOLOGIES</b>
	HEALTH-2007-3.1-1: Implementation of research into healthcare practice. (SM)	HEALTH-2009-3.1-1: Patient Safety: Effective implementation of prevention strategies for healthcare associated infections. (SM)	HEALTH-2010-3.1-1. Better understanding of dissemination and implementation strategies (SM-3)		Closed	Priority
	HEALTH-2007-3.1-2: Self-medication and patient safety. NOT COVERED - (SM)	HEALTH-2009-3.1-2: Improve quality and safety of hospital care. (SM)			Closed	
	HEALTH-2007-3.1-3: Patient Safety Research Network. (CSA)	HEALTH-2009-3.1-3: Complementary and Alternative Medicine. (CSA)			Closed	
	HEALTH-2007-3.1-4: Improving clinical decision making. (SM)	HEALTH-2009-3.1-4: Improved treatment of chronic diseases in developing countries. (SM)			Closed	
	HEALTH-2007-3.1-5: Better use of medicines. (SM)				Closed	
	HEALTH-2007-3.1-6: Continuity of clinical care. (SM)				Closed	
	HEALTH-2007-3.1-7: Patient self-management of chronic disease. NOT COVERED - (SM)				Closed	
<b>AREA 3.2. QUALITY, EFFICIENCY AND SOLIDARITY OF HEALTHCARE SYSTEMS INCLUDING TRANSITIONAL HEALTH SYSTEMS</b>	<b>AREA 3.2. QUALITY, EFFICIENCY AND SOLIDARITY OF HEALTHCARE SYSTEMS INCLUDING TRANSITIONAL HEALTH SYSTEMS</b>	<b>AREA 3.2. QUALITY, EFFICIENCY AND SOLIDARITY OF HEALTHCARE SYSTEMS INCLUDING TRANSITIONAL HEALTH SYSTEMS</b>	<b>AREA 3.2. QUALITY, EFFICIENCY AND SOLIDARITY OF HEALTHCARE SYSTEMS INCLUDING TRANSITIONAL HEALTH SYSTEMS</b>	<b>AREA 3.2. QUALITY, EFFICIENCY AND SOLIDARITY OF HEALTHCARE SYSTEMS INCLUDING TRANSITIONAL HEALTH SYSTEMS</b>	<b>AREA 3.2. QUALITY, EFFICIENCY AND SOLIDARITY OF HEALTHCARE SYSTEMS INCLUDING TRANSITIONAL HEALTH SYSTEMS</b>	<b>AREA 3.2. QUALITY, EFFICIENCY AND SOLIDARITY OF HEALTHCARE SYSTEMS INCLUDING TRANSITIONAL HEALTH SYSTEMS</b>
	HEALTH-2007-3.2-1: Evaluation of disease management programmes. (SM)	HEALTH-2009-3.2-1: Organisation of dementia care. (SM)	HEALTH-2010-3.2-1. Financing systems' effect on quality of healthcare (SM-3)		HEALTH.2012.3.2-1: Improving the organisation of health service delivery. FP7-HEALTH-2012-INNOVATION-1	Closed
	HEALTH-2007-3.2-2: Health systems and long term care of the elderly. (SM)	HEALTH-2009-3.2-2: Healthcare outcomes and cost benefits. (SM)	HEALTH-2010-3.2-2. Risk adjustment algorithms for better health insurance coverage (SM-3)			
	HEALTH-2007-3.2-3: Mobility of health professionals. (SM)	HEALTH-2009-3.2-3: Primary care quality linkage to costs. (SM)				
	HEALTH-2007-3.2-4: Health care human resource planning in nursing. (SM)	HEALTH-2009-3.2-4: Impact of cross border collaboration on health services. (SM)				
	HEALTH-2007-3.2-5: Clinician working time and patient safety. (SM)	HEALTH-2009-3.2-5: Research access to comparable healthcare data. (CSA)				
	HEALTH-2007-3.2-6: Health outcome measures and population ageing. (SM)	HEALTH-2009-3.2-6: Scoping study to address the methodological challenges of quantifying the socio-economic burden of brain diseases in the enlarged European Union compared to other major diseases. (CSA)				
	HEALTH-2007-3.2-7: Trends of population health. (SM)					
	HEALTH-2007-3.2-8: European system of Diagnosis-related groups (DRG). (SM)					





AREA 4.1. COORDINATION AND SUPPORT ACTIONS ACROSS THE THEME	AREA 4.1. COORDINATION AND SUPPORT ACTIONS ACROSS THE THEME	AREA 4.1. COORDINATION AND SUPPORT ACTIONS ACROSS THE THEME	AREA 4.1. COORDINATION AND SUPPORT ACTIONS ACROSS THE THEME	AREA 4.1. COORDINATION AND SUPPORT ACTIONS ACROSS THE THEME	AREA 4.1. COORDINATION AND SUPPORT ACTIONS ACROSS THE THEME	AREA 4.1. COORDINATION AND SUPPORT ACTIONS ACROSS THE THEME
HEALTH-2007-4.1-1: Reinforcing the network of National Contact Points (NCP) for the Seventh Framework Programme under Health Theme by promoting trans-national co-operation. (CSA)	HEALTH-2007-4.1-8: Promotion and facilitation of international cooperation in areas relevant to the objectives of this Theme. (CSA)	HEALTH-2009-4.1-1: Monitoring tool and technology transfer analysis for health grants during FP7. (CSA)	HEALTH-2010-4.1-1. Promoting participation of high-technology research-intensive SMEs, operating in the Health sector (CA)	HEALTH.2011.4.1-1: Networking of major research institutions to coordinate communication actions aimed to the media and the general public (CA-2)	HEALTH.2012.4.1-1: Network to encourage knowledge transfer activity in FP-funded health research (especially in academic and governmental organisations). FP7-HEALTH-2012-INNOVATION-1. (CSA-2)	Open
HEALTH-2007-4.1-2: Promoting participation of high-technology research intensive SMEs, operating in the biomedical engineering and other medical technology sectors relevant to Health Theme. (CSA)		HEALTH-2009-4.1-2: Dissemination of results from research in Life Sciences and Biotechnology for Health to the general public and/or information multipliers. (CSA)		HEALTH.2011.4.1-2: Targeting publication bias (SA-0,5+)	HEALTH.2012.4.1-2: Training actions linked to intellectual property rights management and knowledge transfer. FP7-HEALTH-2012-INNOVATION-1. (CSA-2)	
HEALTH-2007-4.1-3: Assessment and valorisation of project outcome for high-technology and research intensive SME participating to Framework Programmes of Research in the healthcare sector. (CSA)		HEALTH-2009-4.1-3: Targeting publication bias. (CSA)			HEALTH.2012.4.1-3: Support for Presidency events: Organisation of supporting actions and events related to the Presidency of the European Union. FP7-HEALTH-2012-INNOVATION-1. (CSA-+0,1)	
HEALTH-2007-4.1-4: Identifying patients' needs in the clinical trials context. (CSA)					HEALTH.2012.4.1-4: Communicating the benefits of European research to the general public. FP7-HEALTH-2012-INNOVATION-1. (CSA-1+)	
HEALTH-2007-4.1-5: Science communication actions. (CSA)					HEALTH.2012.4.1-5: Preparing the future for health research and innovation. FP7-HEALTH-2012-INNOVATION-1. (CSA-0,5+)	
HEALTH-2007-4.1-6: Initiatives to foster dialogue and debate on health research issues of interest to the public. (CSA)						
HEALTH-2007-4.1-7: Studies on impact of EU legislations on health research and related developments and applications. (CSA)						
AREA 4.2. RESPONDING TO EU POLICY NEEDS	AREA 4.2. RESPONDING TO EU POLICY NEEDS	AREA 4.2. RESPONDING TO EU POLICY NEEDS	AREA 4.2. RESPONDING TO EU POLICY NEEDS	AREA 4.2. RESPONDING TO EU POLICY NEEDS	AREA 4.2. RESPONDING TO EU POLICY NEEDS	AREA 4.2. RESPONDING TO EU POLICY NEEDS
HEALTH-2007-4.2-3: Research to assess the economic dimension of occupational health and safety. (CSA)	HEALTH-2007-4.2-1: Adapting off-patent medicines to the specific needs of paediatric populations. (SM)	HEALTH-2009-4.2-1: Adapting off-patent medicines to the specific needs of paediatric populations. (SM)	HEALTH-2010-4.2-1. Off-Patent Medicines for Children (SM-6)	HEALTH-2011-4.2-1: Off-Patent medicines for children (SM-6+)	Closed	Open
HEALTH-2007-4.2-4: Health statistics and rare events. (SM)	HEALTH-2007-4.2-2: Relative safety of non-steroidal anti-inflammatory drugs (NSAIDs). (SM)	HEALTH-2009-4.2-2: Study of the Arrhythmogenic potential of different classes of medicines. (SM)	HEALTH-2010-4.2-2. International Paediatric initiative (NoE)	HEALTH.2011.4.2-2. Adverse Drug Reaction Research (SM-3+)	Closed	
	HEALTH-2007-4.2-5: Effectiveness of fiscal policies for tobacco control in Europe. (SM)	HEALTH-2009-4.2-3: Human Papillomavirus Vaccination (HPV) and cervical cancer screening programmes: estimate of impact of different policy options by way of disease modelling and health economics. (SM)	HEALTH-2010-4.2-3. Adverse Drug Reaction Research (SM-3)	HEALTH.2011.4.2.3: New methodologies for clinical trials in personalised medicine (SM-SME-3-+)	Closed	
		HEALTH-2009-4.2-4: Coordinating action on organ procurement and transplantation with a focus on new EU Member States. (CSA)	HEALTH-2010-4.2-4. International Pluripotent Stem Cell Registry (CA)		Closed	
			HEALTH-2010-4.2-5. Methodology to evaluate and monitor health policy implementation and performance of EU funded interventions in developing countries (SM-3-ICPC)		Closed	
			HEALTH-2010-4.2-6. Impact of EU legislation on health research (SA)		Closed	
			HEALTH-2010-4.2-7. International forum for European life sciences funders and performers (CA)		Closed	
			HEALTH-2010-4.2-8. Coordination action in support of the implementation by participating States of a Joint Programming Initiative for combating neurodegenerative diseases, in particular Alzheimer's disease (CA)		Closed	
			HEALTH-2010-4.2-9. Towards the replacement of repeated dose systemic toxicity testing in human safety assessment		Closed	
			4.2.9.1. Optimisation of current methodologies and development of novel methods to achieve functional differentiation of human-based target cells in vitro (JRI-min.8 - max.10)		Closed	
			4.2.9.2. Exploitation of organ-simulating cellular devices as alternatives of long-term toxicity testing (JRI-min. 8 -max10)		Closed	
			4.2.9.3.Establishment of endpoints and intermediate markers in human-based target cells with relevance for repeated dose systemic toxicity testing (JRI-min.7 - max.9)		Closed	
			4.2.9.4.Computational modelling and estimation techniques (JRI-min.5 - max.7)		Closed	



			4.2.9.5.Systems biology for the development of predictive casual computer models (JRI-min.8 - max.10)		Closed	
			4.2.9.6.Integrated data analysis and servicing (JRI-min.4 - max.6)		Closed	
			4.2.9.6.Coordination project (JRI-CA- max.3)		Closed	
<b>AREA 4.3. SPECIFIC INTERNATIONAL COOPERATION ACTIONS (SICA)</b>	<b>AREA 4.3. SPECIFIC INTERNATIONAL COOPERATION ACTIONS (SICA)</b>	<b>AREA 4.3. SPECIFIC INTERNATIONAL COOPERATION ACTIONS (SICA)</b>	<b>AREA 4.3. SPECIFIC INTERNATIONAL COOPERATION ACTIONS (SICA)</b>	<b>AREA 4.3. SPECIFIC INTERNATIONAL COOPERATION ACTIONS (SICA)</b>	<b>AREA 4.3. SPECIFIC INTERNATIONAL COOPERATION ACTIONS (SICA)</b>	<b>AREA 4.3. SPECIFIC INTERNATIONAL COOPERATION ACTIONS (SICA)</b>
4.3.1. NEGLECTED INFECTIOUS DISEASES	4.3.1. NEGLECTED INFECTIOUS DISEASES	4.3.1. NEGLECTED INFECTIOUS DISEASES	4.3.1. NEGLECTED INFECTIOUS DISEASES	4.3.1. NEGLECTED INFECTIOUS DISEASES	4.3.1. NEGLECTED INFECTIOUS DISEASES	4.3.1. NEGLECTED INFECTIOUS DISEASES
See 2.3.3	See 2.3.4	See 2.3.4	See 2.3.4	See 2.3.4		
4.3.2. INTERNATIONAL PUBLIC HEALTH AND HEALTH SYSTEMS	4.3.2. INTERNATIONAL PUBLIC HEALTH AND HEALTH SYSTEMS	4.3.2. INTERNATIONAL PUBLIC HEALTH AND HEALTH SYSTEMS	4.3.2. INTERNATIONAL PUBLIC HEALTH AND HEALTH SYSTEMS	4.3.2. INTERNATIONAL PUBLIC HEALTH AND HEALTH SYSTEMS	4.3.2. INTERNATIONAL PUBLIC HEALTH AND HEALTH SYSTEMS	4.3.2. INTERNATIONAL PUBLIC HEALTH AND HEALTH SYSTEMS
See 3.X.	See 3.X.	See 3.X.	See 3.X.	See 3.X.		
4.3.3. COORDINATED TOPICS	4.3.3. COORDINATED TOPICS	4.3.3. COORDINATED TOPICS	4.3.3. COORDINATED TOPICS	4.3.3. COORDINATED TOPICS	4.3.3. COORDINATED TOPICS	4.3.3. COORDINATED TOPICS
		HEALTH-2009-4.3.3-1 Comparative population genetic studies on multifactorial diseases. (SICA-Russia) - (SM)				
		HEALTH-2009-4.3.3-2: Mechanisms of diabetic and weight-related co-morbidity in heart failure (SICA-Russia) - (SM)				